TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more
TaiMed Biologics (4147) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.029x
Based on the latest financial reports, TaiMed Biologics (4147) has a cash flow conversion efficiency ratio of 0.029x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$115.29 Million) by net assets (NT$3.92 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TaiMed Biologics - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how TaiMed Biologics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
TaiMed Biologics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TaiMed Biologics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Boiln Plastics Co. Ltd.
SHE:301003
|
0.029x |
|
Foresee Pharmaceuticals Co Ltd
TWO:6576
|
-0.162x |
|
NUEV.EXP.TEX.INH.EO-016
F:B02
|
N/A |
|
Foosung
KO:093370
|
0.115x |
|
Cartesian Growth Corporation III Class A Ordinary Shares
NASDAQ:CGCT
|
-0.001x |
|
K&F Growth Acquisition Corp. II Class A Ordinary shares
NASDAQ:KFII
|
-0.002x |
|
Triveni Engineering & Industries Limited
NSE:TRIVENI
|
0.012x |
|
PKSHA TECHNOLOGY INC.
F:762
|
N/A |
Annual Cash Flow Conversion Efficiency for TaiMed Biologics (2015–2024)
The table below shows the annual cash flow conversion efficiency of TaiMed Biologics from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$4.02 Billion | NT$-379.55 Million | -0.094x | -845.68% |
| 2023-12-31 | NT$2.57 Billion | NT$-25.60 Million | -0.010x | +95.52% |
| 2022-12-31 | NT$2.71 Billion | NT$-605.21 Million | -0.223x | -210.36% |
| 2021-12-31 | NT$2.94 Billion | NT$-211.28 Million | -0.072x | -21.50% |
| 2020-12-31 | NT$3.42 Billion | NT$-201.94 Million | -0.059x | +67.65% |
| 2019-12-31 | NT$3.59 Billion | NT$-655.31 Million | -0.183x | -42.60% |
| 2018-12-31 | NT$4.08 Billion | NT$-522.86 Million | -0.128x | -6.49% |
| 2017-12-31 | NT$4.29 Billion | NT$-516.48 Million | -0.120x | -229.21% |
| 2016-12-31 | NT$4.71 Billion | NT$-172.29 Million | -0.037x | +59.87% |
| 2015-12-31 | NT$4.90 Billion | NT$-446.26 Million | -0.091x | -- |